FOLD vs. RGEN, HALO, MDGL, IONS, ALKS, LGND, BCRX, CLDX, INVA, and DVAX
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry.
Amicus Therapeutics vs. Its Competitors
Repligen (NASDAQ:RGEN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.
In the previous week, Repligen had 6 more articles in the media than Amicus Therapeutics. MarketBeat recorded 11 mentions for Repligen and 5 mentions for Amicus Therapeutics. Repligen's average media sentiment score of 0.79 beat Amicus Therapeutics' score of 0.54 indicating that Repligen is being referred to more favorably in the media.
97.6% of Repligen shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Repligen currently has a consensus price target of $172.83, indicating a potential upside of 36.69%. Amicus Therapeutics has a consensus price target of $16.22, indicating a potential upside of 177.78%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Repligen.
Repligen has a net margin of -3.93% compared to Amicus Therapeutics' net margin of -5.41%. Amicus Therapeutics' return on equity of 4.67% beat Repligen's return on equity.
Repligen has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
Repligen has higher revenue and earnings than Amicus Therapeutics. Repligen is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Repligen beats Amicus Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FOLD) was last updated on 7/1/2025 by MarketBeat.com Staff
